GTBP: GT Biopharma Corporation Price-to-Revenue Multiple

Symbol and logo of brand GT Biopharma Inc (GTBP)

GT Biopharma, Inc. (GTBP) utilizes cGMP facilities for protein production to minimize supply chain risks. The innovative TriKE platform directs immunity toward tumors, outperforming standard therapy. Engaging CRO vendors for clinical trials while maintaining full patent ownership eliminates external dependency. P/S volatility helps align market value with revenue, with the parameter stabilizing at .

GTBP - gtbiopharma.com Market Cap to Revenue over the range 07/04/2022 - 11/14/2026

Analytical breakdowns for GT Biopharma Corp (GTBP)

- stock price and consensus target price:
Share Price gtbiopharma.com|GTBP - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization GT Biopharma Corp|GTBP - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share GT Biopharma|GTBP - Company Net Assets|Market Value to Book Value gtbiopharma.com|GTBP - Company Total Assets
- business debt structure and liquidity details:
Debt to Equity GT Biopharma, Inc.|GTBP - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient GT Biopharma Corporation|GTBP - Company Debts|Debts to Book Value GT Biopharma Corp|GTBP - Company Long-Term Debt|Current Liabilities GT Biopharma|Intermediate Coverage Ratio gtbiopharma.com
- earnings and market ratios statistics:
GTBP - Net Profit|Projected Future Earnings GT Biopharma, Inc.|GTBP - Price to Earnings Ratio|Future Price to Earnings Multiple GT Biopharma Inc|GTBP - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio GT Biopharma Corp|GTBP - Operating profit EBITDA|Net earnings per share (EPS TTM) GT Biopharma|GTBP - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months gtbiopharma.com|GTBP - Earnings growth in current year|Consensus forecast of earnings per share growth for next year GT Biopharma, Inc.
- sales revenue and business income indicators:
GTBP - Company Revenue|Company Revenue Forecast gtbiopharma.com|GTBP - P/S Multiple|Forward Price-to-Revenue Multiple GT Biopharma Corp
Fundamental company analysis:GTBP - gtbiopharma.com
Product sample of GT Biopharma, Inc.

The market value dynamics of GT Biopharma, Inc. (GTBP) relative to its operating income allow for an assessment of business resilience to volatility, particularly given the risks of capital dilution and drug toxicity. By analyzing the price-to-sales ratio, an investor can determine how much the market is willing to pay per unit of sales, which helps identify asset overvaluation amid fierce competition in the cancer immunotherapy sector.

Competitors of GT Biopharma, Inc.

tgtherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple ACLX (Arcellx, Inc.)|Price-to-Revenue Multiple Disc Medicine Inc|SNDX: Market Cap to Revenue|Kura - Market Cap to Sales Volume|ADCT (ADC Therapeutics) - Market Cap to Revenue|Foghorn Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|VOR (Vor Biopharma) - P/S Multiple|Price-to-Revenue Ratio NKTX|P/S Multiple COEP|Price-to-Revenue Coefficient Actinium Corp|Price-to-Revenue Ratio Estrella Immunopharma ESLA|CASI Pharmaceuticals Inc. (CASI) - Price to Sales|MRKR - Price-to-Revenue Ratio|Price-to-Sales Ratio INAB|ERNA: P/S Multiple|Aptose Biosciences - Market Capitalization-to-Revenue Ratio|BPTH (Bio-Path Holdings) - P/S Multiple|P/S Multiple meipharma.com|Price-to-Revenue Ratio Vincerx Pharma, Inc. (VINC)